Collin Todd

Collin Todd serves as the Head of Strategy & Business Development at Odyssey Therapeutics since December 2021 and is a Board Observer at CTRL Therapeutics. Prior experience includes Sr. Director, Strategy & Business Development at SpringWorks Therapeutics, where significant achievements encompassed multiple collaborations and agreements with esteemed institutions such as DFCI, Stanford, and Janssen, alongside a successful $410M asset sale to Jazz Pharma. Further notable roles include Sr. Manager, Strategic Planning at Moderna, where strategic initiatives for product lifecycle improvement were spearheaded, and Analyst positions at OrbiMed and Merrill Lynch, contributing to substantial venture capital fundraisings and significant M&A transactions. Collin Todd holds a Bachelor of Arts in Economics from UCLA.